Relapsed/Refractory AML
Conditions
Keywords
AML
Brief summary
This study will evaluate the safety and tolerability of uproleselan(GMI-1271), a specific E-selectin antagonist, and characterize the pharmacokinetic (PK) profile of uproleselan, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients.
Detailed description
This study is a multicenter open-labelled study conducted in subjects with relapsed or refractory AML in China. The study includes the following phases: screening phase, induction phase, consolidation phase baseline, consolidation phase and follow-up period. Screening phase: This study will enroll 12 subjects, who are 18 to 60 years (inclusive) at the time of signing the Informed Consent Form (ICF), and with the diagnosis as relapsed or refractory AML. Screening is conducted 21 days to 2 days before administration, and signed ICF by the subject must be obtained before screening. Baseline period: The baseline period is 1 day before study drug administration. Induction treatment: During the induction phase, subjects will receive 8 consecutive days of uproleselan treatment and 5 consecutive days of MEC (mitoxantrone, etoposide, and cytarabine combined regimen) chemotherapy. Consolidation baseline: The baseline of the consolidation phase is 1 day before the treatment administration of the consolidation phase. Consolidation treatment: Subjects who met the criteria for consolidation treatment started the consolidation period at the 29th day of the previous treatment cycle at the earliest and the 65th day at the latest. Follow-up period: Each subject should complete the following follow-up stage: (1) Response evaluation to determine remission to the induction treatment (induction period); (2) EOT assessment after completing the last consolidation treatment cycle; (3) Death. Survival and long-term follow-up, including initiation of new anti-leukemia treatment (within 6 months after the last uproleselan/placebo administration), recurrence, HSCT and survival events, monthly (±14 days) for 2 years after the end of treatment, and afterwards quarterly (±14 days). The longest survival follow-up time is 3 years (calculated from the start of treatment).
Interventions
DRUGUproleselan
A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
Sponsors
Apollomics Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. ≥18 years and ≤60 years in age 2. AML (including secondary AML) diagnosed as per WHO standards (2008). 3. For refractory AML, only cytarabine/daunorubicin(or Idarubicin) as can be applied repeatedly(maximal twice) as induction, no other chemotherapy are allowed to be applied Venatoclax /hypomethylation drug \[HMA\] can be used before and after chemotherapy. 1. For relapse AML, it must be the first or second relapse, and remain untreated. 2. Certain regimens (Venatoclax/HMA, Venetoclax/LDAC, HMA single agent) and FLT3 inhibitors, tyrosine kinase inhibitors, IDH1/IDH2 inhibitors or similar targeted inhibitors used alone are not considered cytotoxic chemotherapy are allowed. 4. ECOG performance status score is 0 to 2. 5. Stable hemodynamics and good organ function.
Exclusion criteria
1. Patients with acute promyelocytic leukemia, acute leukemia of ambiguous lineage (biphenotypic leukemia), chronic myeloid leukemia with myeloid blast crisis, or secondary refractory AML. 2. Active signs or symptoms of CNS involvement by malignancy. 3. Stem cell transplantation ≤4 months prior to dosing. 4. Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing. 5. Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing. 6. Inadequate organ function. 7. Abnormal liver function. 8. Known active infection with hepatitis A, B, or C, or human immunodeficiency virus. 9. Moderate kidney dysfunction (glomerular filtration rate \<45 mL/min). 10. Uncontrolled acute life-threatening bacterial, viral, or fungal infection. 11. Clinically significant cardiovascular disease. 12. Major surgery within 4 weeks of dosing.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The tolerance of participants with relapsed/refractory AML. | Up to 10 months | Number of participants could tolerate the Uproleselan combined with chemotherapy. |
| Area under the plasma concentration-time curve from time zero to 12 hours (AUC0-12) | 14 days | To assess the pharmacokinetic profile in patients with relapsed/refractory AML. |
| The area under the plasma concentration-time curve (AUC0-t) from time zero to the last measurable time point | 14 days | To assess the pharmacokinetic profile in patients with relapsed/refractory AML. |
| The Incidence of Adverse Events | Up to 10 months | Number of participants with an AE. |
| Peak plasma concentration (Tmax) | 14 days | To assess the pharmacokinetic profile in patients with relapsed/refractory AML. |
| Peak plasma concentration (Cmax) | 14 days | To assess the pharmacokinetic profile in patients with relapsed/refractory AML. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Remission rate (rate of CR, CR/CRi and CR/CRh) | Up to 60 days | Defined as the rate of subjects who reach CR, CR/CRi and CR/CRh; |
| CTCAE grade 3 and 4 oral mucositis | Up to 254 days | The incidence of CTCAE grade 3 and 4 oral mucositis during the treatment duration. |
| OS | Up to 3 years | Defined as the period from when the subject receives the first dose of the study drug to death from any cause; |
Countries
China
Outcome results
None listed